Wahren B, Lidbrink E, Wallgren A, Eneroth P, Zajicek J
Cancer. 1978 Oct;42(4):1870-8. doi: 10.1002/1097-0142(197810)42:4<1870::aid-cncr2820420426>3.0.co;2-y.
50 patients with primary breast cancer were studied to determine the CEA and HCG contents in their tumor cells before any treatment was initiated. Tumor cells were obtained by needle biopsy and each tumor cell population was stained by immunofluorescence. In 21 of the 50 patients, CEA containing cells were found in a frequency ranging from 5 to 80% of the tumor cell population. The results were confirmed by radioimmunoassay of tumor extracts. No apparent relation was seen to cytologic type or grade of differentiation. HCG was detected by IF in 4 tumors with an apocrine cytologic cell type. The level of CEA in plasma was determined before treatment and followed for 2-6 months in 72 patients. CEA was the only measured serum parameter that correlated initially with size and extent of the localized tumor. It was too low to be of use for monitoring primary disease, but should be of value in early detection of metastasis. Posttreatment a low or decreased plasma CEA was seen more often in patients who had had curative treatment than in those given palliative radiation. No raised serum HCG levels were found. Raised serum liver enzymes did not predict the extent of the primary tumor but may be an indication of distant spread. Tumor CEA content and CEA plasma concentration were correlated, although not very strongly. This means that CEA, although present in the tumor, is not always released in measurable amounts.
对50例原发性乳腺癌患者进行了研究，以确定在开始任何治疗之前其肿瘤细胞中的癌胚抗原（CEA）和人绒毛膜促性腺激素（HCG）含量。通过针吸活检获取肿瘤细胞，并用免疫荧光对每个肿瘤细胞群体进行染色。在50例患者中的21例中，发现含有CEA的细胞，其在肿瘤细胞群体中的频率范围为5%至80%。肿瘤提取物的放射免疫测定证实了结果。未发现与细胞学类型或分化程度有明显关系。在4例具有大汗腺细胞学类型的肿瘤中通过免疫荧光检测到HCG。在72例患者中，在治疗前测定血浆CEA水平，并随访2至6个月。CEA是唯一最初与局部肿瘤大小和范围相关的测量血清参数。其水平过低，无法用于监测原发性疾病，但在早期转移检测中应具有价值。治疗后，接受根治性治疗的患者比接受姑息性放疗的患者更常出现血浆CEA降低或下降。未发现血清HCG水平升高。血清肝酶升高不能预测原发性肿瘤的范围，但可能是远处转移的一个指标。肿瘤CEA含量与血浆CEA浓度相关，尽管相关性不是很强。这意味着CEA虽然存在于肿瘤中，但并不总是以可测量的量释放。
